MANILA, July 8 — From spotting breast cancer in a mammogram to predicting the shape of millions of proteins, artificial intelligence is quietly reshaping what’s possible in medicine. For communities across Asia, where access to specialists can be uneven and diagnostic backlogs are common, these advances carry particular promise. A 2020 study published in Nature by researchers at Google Health demonstrated that an AI system could detect breast cancer in mammograms with greater accuracy than human radiologists.
The system reduced false positives by 5.7 percent and false negatives by 9.4 percent. For families in the region, fewer false positives means less unnecessary anxiety and fewer invasive follow-up procedures.
Fewer false negatives means cancers caught earlier, when treatment is more likely to succeed.
Machines that see what humans miss
Machine learning algorithms, a subset of artificial intelligence, are now being used to analyze medical images, patient data, and genomic information to assist in disease detection. The technology is not replacing doctors but giving them a second set of eyes — one that never gets tired and can scan thousands of images with consistent attention. In drug discovery, the impact has been equally striking.
DeepMind’s AlphaFold, announced in 2020, predicted protein structures for hundreds of thousands of proteins. This breakthrough accelerates the identification of drug targets, a process that traditionally took years of laboratory work.
For a region like Southeast Asia, where pharmaceutical research capacity varies widely, such tools could help local scientists design treatments for diseases that disproportionately affect their populations. The numbers tell a story of rapid growth. The global AI in healthcare market was valued at $6.7 billion in 2020 and is projected to reach $67.4 billion by 2027, according to a 2021 report by Allied Market Research.
That is nearly a tenfold increase in seven years.
Approvals and oversight
As of 2023, the U.S. Food and Drug Administration had approved over 500 AI-based medical devices. These range from software that reads chest X-rays to algorithms that help detect diabetic retinopathy in retinal scans. The pace of approvals signals that regulators are taking the technology seriously, even as they grapple with how to evaluate systems that can learn and change over time.
Dr. Eric Topol, author of Deep Medicine (2019), has written extensively about how AI could restore the human connection in healthcare by automating routine tasks and freeing clinicians to spend more time with patients. Dr. Fei-Fei Li, co-director of Stanford’s Human-Centered AI Institute, has advocated for systems designed with people — not just performance metrics — at the center.
But the technology also raises serious questions. Data privacy is a concern when algorithms train on millions of patient records. Algorithmic bias — where a system performs less accurately for certain racial or ethnic groups — is a documented risk.
And the role of human clinicians in an increasingly automated environment remains a subject of debate.
What it means for the region
Closer to home, these developments matter for families across Asia. In many countries, radiologists are in short supply. An AI tool that can triage chest X-rays or flag suspicious mammograms could help health systems stretch limited expertise further.
For rural communities, where the nearest specialist may be hours away, a reliable AI screening tool could mean the difference between early detection and late-stage diagnosis. The ethical and regulatory questions are not abstract.
How do you ensure an algorithm trained largely on data from Western populations works accurately for a patient in a rural Philippine clinic? Who is liable when an AI system makes a mistake? These are conversations that policymakers, clinicians and community leaders across the region are only beginning to have.
What is clear is that the technology is moving fast. The market is growing.
The approvals are coming. And for communities that have long faced barriers to quality healthcare, the promise of AI in medicine is not just about innovation — it is about access. The next few years will show whether that promise can be delivered equitably.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “AI Transforms Medicine: Diagnosis and Drug Discovery”, “description”: “MANILA, July 8 — From spotting breast cancer in a mammogram to predicting the shape of millions of proteins, artificial intelligence is quietly reshaping what’s…”, “datePublished”: “2026-07-08T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Merry Gel Sigui”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
